# Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

> **NCT00311636** · PHASE3 · COMPLETED · sponsor: **Gruppo Italiano Mammella (GIM)** · enrollment: 280 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** docetaxel
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** epirubicin hydrochloride
- **DRUG:** fluorouracil
- **DRUG:** methotrexate
- **DRUG:** paclitaxel
- **DRUG:** triptorelin
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00311636
- **Lead sponsor:** Gruppo Italiano Mammella (GIM)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2008-01
- **Final completion:** 2008-04
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2013-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00311636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00311636, "Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00311636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*